Research and Development Pipeline

Adult stem cells have been suggested as potential treatments for a multitude of diseases and injuries. As one of the leading companies in the regenerative medicine field, Parcell is committed to harnessing the true potential of its ELA cell platform technology, and is currently involved in active Research and Development with the ultimate aim of developing a large and diversified portfolio of ELA cell-based therapeutic modalities.

Intervertebral Disc Regeneration

The use of stem cells as a treatment for spinal morbidities is not limited to their mediation of spinal fusion. Fraying and splitting of the intervertebral disks occur frequently with age, impacting the quality of life of millions of people each year. Evidence suggests that adult stem cells can delay disc degeneration and maintain disc integrity and promising evidence already exists to support a role for the ELA cell in cartilage regeneration directing Parcell to evaluate the use of ELA cells as a next generation therapy for degenerative disc disease.

Immune Suppression

Current research in the stem cell field suggests that Adult Stem Cells can act as natural immunosuppressive therapies, primarily by activation of cytokine signaling which leads to the suppression of both the acute and chronic lymphocytic response.

In diseases of the joint, for example, the data indicate the potential of the ELA cell to reduce inflammation and/or suppress the autoimmune response, thereby slowing disease progression. This immune suppression property, however, is not limited to diseases of the joints. Parcell’s other avenues of investigation include the evaluation of ELA cell-based treatments as potential therapeutics for GVHD and various autoimmune diseases.